East Bay Rheumatology Medical Group conducts cutting-edge research in Rheumatoid Arthritis, Lupus, Osteoarthritis other Rheumatic and Auto Immune diseases. We work with leading Pharmaceutical Companies and all studies are regulated by the FDA and follow strict legal and ethical codes to protect the interests and welfare of patients. Our goal is to find new and improved medications and treatments that help you with your disease and provide help for others in the future.
If you are interested in one of our clinical trials, please call our Research Department at: 510-357-1040.
Enrolling Clinical Trials at East Bay Rheumatology Research Institute:
Rheumatoid Arthritis (RA):
R-Pharm/ Credo2 – A Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy.
Santarus/ Salix – A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending dose study to Evaluate the Safety Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in patients with Active Rheumatoid Arthritis with inadequate response to Disease Modifying Anti-rheumatic Drugs.
EMD Serono – A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects with Rheumatoid Arthritis on Stable Methotrexate Therapy.
Lupus -Systemic Lupus Erythematosus (SLE) / Lupus Nephritis (LN):
Human Genome Sciences- Lupus Nephritis – A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo Plus Standard of Care in Adults with Active Lupus Nephritis.
Celgene - A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-220 in Subjects with Systemic Lupus Erythematosus.
Astrazeneca – A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus.
ImmuPharma - A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients with Systemic Lupus Erythematosus.
Xencor – A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb5871 on Systemic Lupus Erythematosus Disease Activity.
Merck Serono – A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE).